The abstract is read at the publisher; the summary is JClub's.
Glycoprotein nonmetastatic melanoma protein B overexpression is strongly upregulated in CDK4/6 inhibitor–resistant estrogen receptor-positive breast cancer models and predicts failure of CDK4/6 blockade.
- Why it matters: Resistance to CDK4/6 inhibitors limits treatment for estrogen receptor-positive breast cancer, and clinicians lack reliable biomarkers to select patients likely to benefit.
- What they did: Drug-tolerant persisters to abemaciclib and palbociclib were generated across estrogen receptor-positive breast cancer cell lines, followed by Clariom D transcriptomic profiling and comparison with PEARL trial resistance data; functional testing used in vitro assays and xenografts.
- The result: In xenografts, glycoprotein nonmetastatic melanoma protein B overexpression abrogated abemaciclib growth inhibition and caused nonresponse across treatment arms, while increasing ITGB1/ITGA5 and phospho-AKT (Ser473) and phospho-ERK 1 and 2 (Thr202/204); glembatumumab vedotin reduced viability and showed strong synergy with abemaciclib.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.